Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One Biopharmaceuticals (NASDAQ: DAWN ) is a commercial-stage biotech focused on the development and marketing of mostly one drug: an RAF kinase inhibitor indicated for children with certain forms of brain cancer. The company has vacillated between $1 and$2 billion inI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you d ...